Semax

At a glance

Overview

Semax contains the sequence Met-Glu-His-Phe-Pro-Gly-Pro and is described in the literature as an ACTH-fragment analog. Its relationship to a hormone fragment does not make it equivalent to full-length ACTH or establish an endocrine replacement role. Research has explored stroke recovery, optic-nerve disorders, brain-network changes, and neurochemical effects. The reports vary substantially in size, controls, and endpoints. A small imaging experiment or a change in a blood biomarker answers a different question from whether a treatment improves disability or daily function. That distinction is essential when evaluating claims about memory, concentration, or neurological recovery.

Supporting sources [1] [2] [3] [4]

How it works

Preclinical studies have examined monoamine signaling and neurotrophic or inflammatory pathways. A rodent study found changes in serotonin-related measurements and interactions with amphetamine-related dopamine effects. Such findings demonstrate biological activity in the experimental setting, not a predictable cognitive benefit in humans. A mechanism can also introduce interaction questions; it should not be presented only as a list of potential advantages.

Supporting sources [1] [2] [3] [4]

Clinical reports require careful interpretation

A 1997 stroke report compared 30 Semax-treated patients with 80 controls receiving conventional therapy. A later rehabilitation study assessed functional measures and plasma BDNF. These reports are relevant signals, but their designs and reporting do not provide the same certainty as a large, rigorously blinded, placebo-controlled program. They do not establish enhancement in healthy users.

Supporting sources [1] [2]

A biomarker is not a treatment outcome

Rodent neurotransmitter experiments can help generate hypotheses about how Semax acts. They cannot establish an effective or safe human intervention. Similarly, an imaging-network change may occur without a meaningful improvement in symptoms, independence, or quality of life; those outcomes need direct assessment.

Supporting sources [3]

U.S. review and unresolved safety

FDA’s 2026 compounding evaluation addressed cerebral ischemia, migraine, and trigeminal neuralgia and found insufficient evidence to support effectiveness. It also described safety limitations. The briefing is not a marketing authorization or a final regulatory determination. Injectable and intranasal preparations should not be treated as interchangeable evidence categories.

Supporting sources [4]

Frequently asked questions

Do BDNF or brain-imaging changes prove better cognition?
No. Biomarkers and imaging can show biological activity without demonstrating improved memory, independence, or quality of life. Those outcomes require direct clinical assessment.

Did the 2026 FDA compounding review approve Semax?
No. The briefing was a scientific evaluation for an advisory process, not a marketing authorization. It described important efficacy and safety limitations.

Supporting sources [2] [3] [4]